CORT125134

DRUG5 trials

Sponsors

Corcept Therapeutics Inc., Corcept Therapeutics

Conditions

AdvancedCushing's SyndromeGynecological CancersHealthyHigh-Grade Epithelial OvarianPlatinum-ResistantPrimary Peritonealor Fallopian-Tube Cancer

Phase 1

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

CompletedNCT03508635

Corcept TherapeuticsHealthy

Start: 2014-09-30End: 2015-12-31Updated: 2019-08-09

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

CompletedNCT06094712

Corcept TherapeuticsHealthy

Start: 2016-04-07End: 2016-04-27Updated: 2023-10-23

Phase 2

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

CompletedNCT02804750

Corcept TherapeuticsCushing's Syndrome

Start: 2016-06-30End: 2018-09-30Updated: 2019-10-15

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)

RecruitingCTIS2024-517432-21-00

Corcept Therapeutics Inc.Gynecological Cancers

Start: 2025-05-30Target: 177Updated: 2026-01-27

Phase 3

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Active, not recruitingCTIS2024-514080-25-00

Corcept Therapeutics Inc.Advanced, High-Grade Epithelial Ovarian, or Fallopian-Tube Cancer +2

Start: 2023-04-21Target: 205Updated: 2025-06-27

Related Papers

Relacorilant or surgery improved hemostatic markers in Cushing syndrome.

2024-09-21

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome

Journal of the Endocrine Society2023-10-01

PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome

Journal of the Endocrine Society2022-11-012 citations

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Frontiers in Endocrinology2022-01-0419 citations

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Frontiers in Endocrinology2021-07-1465 citations

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas

Journal of the Endocrine Society2019-04-019 citations